SG11201407544XA - Composition for treatment of warts - Google Patents
Composition for treatment of wartsInfo
- Publication number
- SG11201407544XA SG11201407544XA SG11201407544XA SG11201407544XA SG11201407544XA SG 11201407544X A SG11201407544X A SG 11201407544XA SG 11201407544X A SG11201407544X A SG 11201407544XA SG 11201407544X A SG11201407544X A SG 11201407544XA SG 11201407544X A SG11201407544X A SG 11201407544XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- acid
- warts
- designated states
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE2012/050566 WO2013180606A1 (en) | 2012-05-28 | 2012-05-28 | Composition for treatment of warts |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407544XA true SG11201407544XA (en) | 2014-12-30 |
Family
ID=49673684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407544XA SG11201407544XA (en) | 2012-05-28 | 2012-05-28 | Composition for treatment of warts |
Country Status (15)
Country | Link |
---|---|
US (1) | US10716857B2 (ko) |
JP (1) | JP5934437B2 (ko) |
KR (1) | KR101988693B1 (ko) |
CN (1) | CN104363885A (ko) |
AU (1) | AU2012381141B2 (ko) |
BR (1) | BR112014029590A2 (ko) |
CA (1) | CA2871990C (ko) |
EA (1) | EA026621B1 (ko) |
HK (1) | HK1206633A1 (ko) |
IL (1) | IL235367B (ko) |
MX (1) | MX351512B (ko) |
SG (1) | SG11201407544XA (ko) |
UA (1) | UA111785C2 (ko) |
WO (1) | WO2013180606A1 (ko) |
ZA (1) | ZA201409502B (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3018687B1 (fr) * | 2014-03-19 | 2017-04-14 | Patrick Lepeytre | " composition a base d'acides carboxyliques et son application pour le traitement des hyperkeratoses " - |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN86107485A (zh) * | 1986-10-29 | 1988-05-11 | 陈黄平 | 普通白酒勾兑成名酒香型酒技术 |
US5433950A (en) | 1990-05-07 | 1995-07-18 | Schering-Plough Healthcare Products, Inc. | Flexible collodion compositions |
US5476664A (en) * | 1994-04-15 | 1995-12-19 | Leonard Bloom | Treatment of warts using anthralins and occlusion |
SE513436C2 (sv) * | 1999-01-21 | 2000-09-11 | Astrid Agholme | Användning av en beredning innehållande myrsyra för framställning av ett läkemedel för behandling av vårtor, orsakade av Papillomavirus |
US7780992B2 (en) | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
KR20060104011A (ko) * | 2005-03-29 | 2006-10-09 | 바이오이퀄 아게 | 사마귀 제거, 손발톱 질병의 치료 및 손발톱 관리에적용하기 위한 국소 제형 |
CN1939539A (zh) * | 2005-09-29 | 2007-04-04 | 瑞士商拜欧伊果公司 | 疣、指甲疾病、及指甲保养用之局部配方 |
US8691247B2 (en) * | 2006-12-26 | 2014-04-08 | Ad Lunam Labs Inc. | Skin rejuvenation cream |
PL2190425T3 (pl) | 2007-04-20 | 2016-04-29 | Bioequal Ag | Miejscowo stosowalne środki grzybobójcze do leczenia paznokci |
JP5248040B2 (ja) | 2007-05-25 | 2013-07-31 | リードケミカル株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドン含有貼付剤 |
NL2003419C2 (en) * | 2009-09-01 | 2011-03-02 | Shieldmark Zacco | Composition for tropical application, uses thereof, applicator device and kit of parts. |
EP2460509B1 (en) * | 2010-12-06 | 2017-11-15 | Abbex Ab | Composition for the treatment of warts |
-
2012
- 2012-05-28 US US14/403,007 patent/US10716857B2/en active Active
- 2012-05-28 MX MX2014014278A patent/MX351512B/es active IP Right Grant
- 2012-05-28 UA UAA201412210A patent/UA111785C2/uk unknown
- 2012-05-28 SG SG11201407544XA patent/SG11201407544XA/en unknown
- 2012-05-28 AU AU2012381141A patent/AU2012381141B2/en active Active
- 2012-05-28 CA CA2871990A patent/CA2871990C/en active Active
- 2012-05-28 CN CN201280073392.3A patent/CN104363885A/zh active Pending
- 2012-05-28 EA EA201491927A patent/EA026621B1/ru not_active IP Right Cessation
- 2012-05-28 KR KR1020147032058A patent/KR101988693B1/ko active IP Right Grant
- 2012-05-28 JP JP2015513968A patent/JP5934437B2/ja active Active
- 2012-05-28 WO PCT/SE2012/050566 patent/WO2013180606A1/en active Application Filing
- 2012-05-28 BR BR112014029590A patent/BR112014029590A2/pt not_active Application Discontinuation
-
2014
- 2014-10-28 IL IL235367A patent/IL235367B/en active IP Right Grant
- 2014-12-23 ZA ZA2014/09502A patent/ZA201409502B/en unknown
-
2015
- 2015-07-31 HK HK15107371.7A patent/HK1206633A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EA026621B1 (ru) | 2017-04-28 |
CA2871990A1 (en) | 2013-12-05 |
AU2012381141B2 (en) | 2017-08-31 |
US20150165031A1 (en) | 2015-06-18 |
AU2012381141A1 (en) | 2014-12-18 |
MX2014014278A (es) | 2015-06-04 |
CN104363885A (zh) | 2015-02-18 |
MX351512B (es) | 2017-10-17 |
IL235367B (en) | 2019-05-30 |
KR20150035533A (ko) | 2015-04-06 |
EA201491927A1 (ru) | 2015-05-29 |
HK1206633A1 (en) | 2016-01-15 |
IL235367A0 (en) | 2014-12-31 |
NZ702424A (en) | 2017-02-24 |
CA2871990C (en) | 2019-07-23 |
KR101988693B1 (ko) | 2019-06-12 |
US10716857B2 (en) | 2020-07-21 |
UA111785C2 (uk) | 2016-06-10 |
BR112014029590A2 (pt) | 2017-06-27 |
ZA201409502B (en) | 2017-06-28 |
JP2015517570A (ja) | 2015-06-22 |
JP5934437B2 (ja) | 2016-06-15 |
WO2013180606A1 (en) | 2013-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
SG11201407200TA (en) | Liquid formulation | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201906431UA (en) | Method for the treatment of thromboembolism | |
SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
SG11201804965SA (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201809469QA (en) | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones | |
SG11201408230VA (en) | Therapeutic formulation and methods of treatment | |
SG11201805142RA (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |